key: cord-0023040-qru1o4ne authors: Dominiczak, Anna F.; Meyer, Trudie J. title: Hypertension Update: A Reflection of the Past Decade date: 2021-11-11 journal: Hypertension DOI: 10.1161/hypertensionaha.121.18596 sha: 40d876073ff6a7d7ca79b4de81bce30bf1540807 doc_id: 23040 cord_uid: qru1o4ne nan As technology and our ability to access research and information more easily have evolved in the last 10 years, the most impressive numbers might be better reflected in our more far-reaching impact. Of course, we are most excited to report that our journal Impact Factor increased from 6.87 in 2012 at the beginning of my editorship to 10.19 in 2021, confirming our Journal as the number one journal devoted to basic, population and clinical research serving the international hypertension community. Over the last 10 years, we have also included 3 groups of scientists who previously only rarely published in Hypertension. These are colleagues involved in hypertension in pregnancy, childhood hypertension, and pulmonary hypertension. This strategic decision has added both quality and breadth to the Journal. Some of the most important publishing highlights over the last 10 years were the Hypertension 2017 Clinical Practice Guidelines full text 1 alongside the executive summary 2 and systematic review 3 as well as the Guidelines Conversations, which can be found at: https://www.ahajournals.org/hyp/guidelines2017. Many other Statements and Guidelines have been published, especially in the last 2 years. [4] [5] [6] [7] [8] [9] It was also important to publish the most recent and evolving research during the height of the pandemic that related to hypertension and coronavirus disease 2019 (COVID-19). [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] Much of this research, along with other important, discussion-inducing articles, were highlighted with Editorials, written by leading researchers and experts. It was a goal during my tenure to use Editorials to point readers to impactful articles that might start further discussion among the hypertension community. 30, 31 This series is unique in that the article published after the presentation not only includes discussion points captured during the session but also offers discussants from the audience the opportunity to be included as contributing authors of the article. Every year, the Hypertension editors select the top 2 articles published in the Journal throughout the previous calendar year in each of the 3 article type categories, basic, clinical, and population science. All 6 2021 Top Paper Award articles [32] [33] [34] [35] [36] [37] were published in 2020 and were highly accessed by readers, clearly novel, and have important clinical implications. The 2021 award winning articles span a wide variety of topics including: obesityrelated hypertension, blood-brain barrier dysfunction in hypertension, COVID-19, interleukin-1β inhibition, discrimination and hypertension risk and dietary influence on blood pressure in early childhood. As the Editorial Board has worked diligently over the years, we think that we have succeeded in accomplishing our long-standing goals to (1) publish the highest quality of original basic, clinical, and population research relating to hypertension; (2) increase the readership and scientific importance of Hypertension; (3) provide fair and quick reviews for submitted manuscripts followed by a rapid publication of all accepted articles; (4) serve well the international community of hypertension researchers and practitioners and serve as an important vehicle to achieve the mission of the American Heart Association. Reflecting on 10 years of Hypertension publishing history, the Editors wish to thank our many readers for their time spent reviewing manuscripts, submitting the best research to Hypertension, and providing feedback so that Hypertension remains the premier journal devoted to basic, clinical and population hypertension research. The commitment and energy of our editors, editorial board members, readers, reviewers, authors and editorial office staff are always greatly appreciated. On behalf of the entire editorial team, it is with pleasure that we share with you our achievements of the previous 10 years. PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: a report of the American College of Cardiology on behalf of the American Heart Association Council on Hypertension; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; and Council on Quality of Care and Outcomes Research. Measurement of blood pressure in humans: a scientific statement from the American Heart Association Animal models of hypertension: a scientific statement from the International Society of Hypertension Global Hypertension Practice Guidelines WHO technical specifications for automated non-invasive blood pressure measuring devices with cuff Council on Cardiovascular Radiology and Intervention; Council on Lifelong Congenital Heart Disease and Heart Health in the Young; and Stroke Council. Management of stage 1 hypertension in adults with a low 10-year risk for cardiovascular disease: filling a guidance gap: a scientific statement from the American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; and Council on Clinical Cardiology. Physical activity as a critical component of first-line treatment for elevated blood pressure or cholesterol: who, what, and how?: a scientific statement from the Renin-angiotensin system blockers and the COVID-19 pandemic: at present there is no evidence to Abandon Renin-Angiotensin System Blockers Chronic use of Angiotensin-converting enzyme inhibitors and Angiotensin II receptor blockers is high among intensive care unit patients with non-COVID-19 sepsis but carries a moderately increased risk of death ACE2 (Angiotensin-Converting Enzyme 2), COVID-19, and ACE inhibitor and Ang II (Angiotensin II) receptor blocker use during the pandemic: the pediatric perspective Controversial relationship between Renin-Angiotensin system inhibitors and severity of COVID-19: announcing a Large Multicentre Case-Control Study in Italy Evidence that Renin-Angiotensin system inhibitors should not be discontinued due to the COVID-19 pandemic Decreased mortality of COVID-19 with Renin-Angiotensin-Aldosterone System inhibitors therapy in patients with hypertension: a meta-analysis COVID-19: ACE-2centric infective disease? Comparative impacts of ACE (Angiotensin-Converting Enzyme) inhibitors versus Angiotensin II receptor blockers on the risk of COVID-19 mortality Age and multimorbidity predict death among COVID-19 patients: results of the SARS-RAS Study of the Italian Society of Hypertension Association between Renin-Angiotensin-Aldosterone system inhibitors and COVID-19 infection in South Korea Clinical features of COVID-19 in patients with essential hypertension and the impacts of Renin-angiotensin-aldosterone system inhibitors on the prognosis of COVID-19 patients Redefining cardiac biomarkers in predicting mortality of inpatients with COVID-19 What kind of evidence is needed to dictate practice regarding inhibitors of the Renin-Angiotensin System in COVID-19? Plasma Angiotensin Peptide profiling and ACE (Angiotensin-Converting Enzyme)-2 activity in COVID-19 patients treated with pharmacological blockers of the Renin-Angiotensin System Severe acute respiratory syndrome Coronavirus 2, COVID-19, and the Renin-Angiotensin System: pressing needs and best research practices Butyrate Regulates COVID-19-relevant genes in Gut Epithelial Organoids from normotensive rats of arterial stiffness on all-cause mortality in patients hospitalized with COVID-19 in Spain Antihypertensive drugs and COVID-19 risk: A Cohort Study of 2 million hypertensive patients Could Renin-Angiotensin System inhibitors be protective from severe COVID-19? First-phase ejection fraction, a measure of preclinical heart failure, is strongly associated with increased mortality in patients with COVID-19 CONNed in pregnancy Renovascular hypertension: one size does not fit all: challenges in diagnosis and management Disruption of pressure-induced Ca2+ spark vasoregulation of resistance arteries, rather than endothelial dysfunction, underlies obesity-related hypertension Endothelium-macrophage crosstalk mediates blood-brain barrier dysfunction in hypertension Effects of Angiotensin II receptor blockers and ACE (Angiotensin-Converting Enzyme) inhibitors on virus infection, inflammatory status, and clinical outcomes in patients with COVID-19 and hypertension: A Single-Center Retrospective Study Effects of Interleukin-1β inhibition on blood pressure, incident hypertension, and residual inflammatory risk: a secondary analysis of CANTOS Discrimination and hypertension risk among African Americans in the Jackson Heart Study Influence of dietary approaches to stop hypertension-type diet, known genetic variants and their interplay on blood pressure in early childhood: ABCD Study